**Core tip:** Recurrences of pT1N0 esophageal squamous cell carcinoma (ESCC) after esophagectomy are usually metachronous regional lymph node or distant metastases. We analyzed 199 thoracic pT1N0 ESCC cases who underwent esophagectomy and thoracoabdominal two-field lymphadenectomy. Forty-seven (24%) patients had a recurrence during 3 to 178 (median, 33) mo. Upper thoracic tumor location, angiolymphatic invasion, and submucosal invasion thickness were independent predictors of tumor recurrence, and a nomogram for predicting recurrence-free survival with these three predictors was constructed. These results should be useful for designing optimal individual follow-up and therapy for patients with T1N0 ESCC.

INTRODUCTION
============

Esophageal squamous cell carcinoma (ESCC) is one of the most common fatal malignancies worldwide, and is especially common in East Asia, including China and Japan. The prognosis of superficial (T1) ESCC is poor, compared with T1 gastric or colorectal cancer. The long longitudinally arranged collecting channels and plexuses of lymphatics in the esophageal submucosa account for the clinical observation that T1 esophageal cancer can metastasize not only to the mediastinal lymph nodes, but also to the cervical and abdominal lymph nodes far distant from the primary tumor, and to distant organs as well\[[@B1]-[@B3]\].

The presence of metastasis is the most important prognostic factor for ESCC. The unfavorable prognosis of patients with T1 ESCC is largely due to high rates of both synchronous and metachronous metastases. Recurrences of T1 ESCC after esophagectomy are usually metachronous regional lymph node or distant metastases, and are only infrequently due to anastomotic recurrences. When recurrence occurs, the prognosis is similar in patients who were node-negative or node-positive at the time of the original surgery\[[@B4]\]. Therefore, patients found to have a high risk of recurrence after esophagectomy need additional chemoradiotherapy. However, only a few studies have evaluated the clinicopathological characteristics associated with an increased risk of a postoperative recurrence in pT1N0 ESCC patients. These studies have shown that invasion depth of the primary tumor, lymphovascular invasion, histologic grade, and tumor length are associated with a high risk of recurrence\[[@B5]-[@B8]\]. No previous studies have separately evaluated the clinicopathological characteristics that are associated with distant recurrence or early recurrence in pT1N0 ESCC patients.

We previously reviewed 271 T1 ESCC esophagectomy cases, and established a set of clinicopathological and immunohistochemical indicators to identify patients with a high risk of synchronous regional lymph node metastasis\[[@B9]\]. However, recurrence was observed in quite a few pT1N0 ESCC cases. Thus, the identification of pT1N0 cases at high risk for recurrence is a very important and challenging aspect of the clinical management of these patients, to ensure appropriate use and maximum benefit of additional therapies. In the present study, we followed 199 pT1N0 thoracic ESCC cases in our original esophagectomy case series and investigated the clinicopathological characteristics that were associated with recurrence, distant recurrence, and early recurrence, in order to provide clues to optimal individual therapy.

MATERIALS AND METHODS
=====================

Patients and surgical procedures
--------------------------------

Two hundred and sixteen pT1N0 thoracic ESCC patients received esophagectomy with thoracoabdominal lymphadenectomy, without preoperative chemoradiotherapy, at National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, between February 1990 and January 2004. After excluding those cases with clinical follow-up recorded fewer than 3 mo (*n* = 12) and those who died within 3 mo of surgery (operative death, *n* = 5), we included 199 cases in the current analysis.

For lesions in the upper third of the thoracic segment, a three-phase abdominothoracic McKeown resection was generally performed through a right thoracotomy. For lesions in the middle and lower thirds, esophagectomy was performed on the left side using a single-incision Sweet approach. The tumor location was defined by the position of the center of the largest invasive lesion of each case (continuous invasive tongues were considered as one invasive lesion, but discontinuous invasive tongues separated by normal or dysplastic mucosa were considered as multiple invasive lesions). This study was approved by the Institutional Review Board of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (NCC 2014 G-47), and interpretation of anonymized data was exempted from review by the Office of Human Subject Research Protection of the NIH.

Macroscopic tumor types
-----------------------

Macroscopic tumor types were defined as we previously described\[[@B9]\]. Briefly, we classified the lesions into six types, occult type (Paris classification 0-IIb), erosive type (Paris classification 0-IIc or 0-IIa + IIc), papillary type (Paris classification 0-Ip), plaque-like type (Paris classification 0-Is or 0-IIa), ulcerative type (Paris classification 0-III or 0-III + I), and intraluminal mass (fungating) type (Paris classification 0-Ip)\[[@B10],[@B11]\]. The difference between the papillary type and the intraluminal mass type is that the largest diameter is \< 3 cm and ≥ 3 cm, respectively\[[@B9]\].

Standard histopathological variables
------------------------------------

All histopathological variables were first reviewed and graded independently by three pathologists (LX, SZ, and LR), and discordant cases were reviewed jointly until a consensus was reached. For the patients with multicentric esophageal carcinomas, the histopathological factors for the lesion with the greatest invasion depth were evaluated\[[@B9]\].

Maximum depth of invasion was classified into five levels: m2 (lamina propria mucosae), m3 (muscularis mucosae), sm1, sm2, and sm3 (superficial, middle, and deep thirds of the submucosa, respectively). Degree of differentiation was classified as well, moderate, poor, basaloid or spindle cell/sarcomatoid\[[@B12]\].

Measured histopathological variables
------------------------------------

Tumor thickness (from the surface to the deepest invasive front of cancer nests), submucosal invasion thickness (from the bottom of the muscularis mucosae to the deepest invasive front of the cancer nests), and the diameter of the largest single tongue of invasion were measured microscopically. Submucosal invasion thickness was measured in submucosal cases, and defined as 0 in mucosal cases.

In our previous study\[[@B9]\], 3000 μm for tumor thickness, 2000 μm for submucosal invasion thickness, and 2 cm for the diameter of the largest single tongue of invasion were found to be the best cut points for predicting lymph node metastasis. Thus, we also used these cut points for categorizing these measurements in this study.

Tissue microarray construction and immunohistochemistry
-------------------------------------------------------

Details of the tissue microarray construction and the immunohistochemical staining and scoring for Cyclin D1, EGFR, and VEGF have been described previously\[[@B9]\]. We rescored p53 expression into three groups: weak or patchy (wild type), complete loss (nonsense, frameshift, or splice-site mutation type), and diffuse and strong (missense mutation type). The latter two groups were considered as aberrant p53 expression\[[@B13]\]. In the present study, the correlation between the expression levels of these four markers and tumor recurrence was further analyzed in the pT1N0 cases.

Follow-up
---------

Follow-up and mortality data were mainly gathered from clinical notes. Patients were evaluated at return visits every 3 mo during the first 2 years after treatment, every 6 mo for the following 3 years, and annually thereafter according to hospital policy. At each visit, physical examination, endoscopic examination, and CT scan of the cervix, chest and abdomen were performed. Suspicious recurrences were biopsied. Confirmation of recurrence required imaging or pathological evaluation. Information about tumor recurrence was updated every time the patient came for a follow-up visit. For those patients who did not come for a follow-up visit, data were gathered by phone calls, and/or mail contact with patients or their next of kin. The patients were followed for a median of 72 mo and a maximum period of 263 mo.

Overall survival time was recorded as the number of months from the date of surgery to the date when death occurred, or to the time of last follow-up, at which point, the data were censored. Recurrence-free survival time was recorded as the number of months from the date of surgery to the date when recurrence occurred, or to the time of last follow-up, at which point, the data were censored.

Four cases underwent radiotherapy after esophagectomy, due to upper resection margins being involved by high grade dysplasia or as part of a randomized clinical trial.

Statistical analysis
--------------------

Continuous variables such as age, tumor thickness, and submucosal invasion thickness were analyzed after categorization.

Overall and recurrence-free survival rates were calculated and survival curves were constructed using the Kaplan-Meier method, with significance evaluated by the log-rank test. The associations between clinicopathological characteristics and any recurrence or distant recurrence were determined using univariate Cox proportional hazards analysis. A backward stepwise multivariate Cox proportional hazards analysis was applied for factors achieving a significance level of 0.05 in univariate analysis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were reported.

The associations between clinicopathological parameters and early recurrence (≤ 24 mo after surgery) were evaluated similarly, except using logistic regression analysis.

All the above statistical analyses were performed using SPSS 16.0 for Windows (SPSS, Chicago, IL, United States), with a significance level of 0.05 on two-tailed *P*-values.

A nomogram based on independent predictors for the recurrence-free survival identified by multivariate Cox proportional hazards analysis was constructed using the rms package in R 3.4.2 software.

RESULTS
=======

Clinicopathological features
----------------------------

The clinicopathological features of the 199 pT1N0 ESCC patients are shown in Table [1](#T1){ref-type="table"}. Seventy-one percent of the patients were men. The average age was 56 years, the median age was 57 years, and the age range was 34-77 years. Seventy-two percent of the tumors were found in the middle thoracic region. For all of the 199 patients, a total of 3197 lymph nodes (median, 14) were dissected.

###### 

Summary of clinical, endoscopic, and histopathological characteristics of the 199 pT1N0 esophageal squamous cell carcinoma patients *n* (%)

  **Characteristic**                                                                        **Patients**
  -------------------------------------------------------------- -------------------------- --------------
  Clinical variable                                                                         
  Sex                                                            Male                       142 (71)
                                                                 Female                     57 (29)
  Age (yr)                                                       \< 60                      121 (61)
                                                                 ≥ 60                       78 (39)
  Symptoms                                                       No                         13 (7)
                                                                 Yes                        186 (93)
  Endoscopic variable                                                                       
  Tumor location                                                 Upper thoracic             31 (16)
                                                                 Middle thoracic            143 (72)
                                                                 Lower thoracic             25 (13)
  Tumor size (measured endoscopically)                           \< 2 cm                    59 (30)
  ≥ 2 cm                                                         140 (70)                   
  Macroscopic tumor type                                         Erosive                    73 (37)
                                                                 Papillary                  26 (13)
                                                                 Plaque-like                79 (40)
                                                                 Ulcerative                 9 (5)
                                                                 Intraluminal mass          12 (6)
  Standard histopathological variable                                                       
  Tumor invasion depth level                                     m2                         21 (11)
                                                                 m3                         26 (13)
                                                                 sm1                        18 (9)
                                                                 sm2                        45 (23)
                                                                 sm3                        89 (45)
  Degree of differentiation                                      Well                       39 (20)
                                                                 Moderate                   76 (38)
                                                                 Poor                       56 (28)
                                                                 Basaloid                   19 (10)
                                                                 Spindle cell/sarcomatoid   9 (5)
  Angiolymphatic invasion                                        No                         172 (86)
                                                                 Yes                        27 (14)
  Multicentric invasive lesions                                  No                         183 (92)
                                                                 Yes                        16 (8)
  Number of lymph nodes dissected                                \< 14                      90 (45)
                                                                 ≥ 14                       109 (55)
  Measured histopathological variables                                                      
  Tumor thickness                                                \< 3000 μm                 85 (43)
                                                                 ≥ 3000 μm                  114 (57)
  Submucosal invasion thickness                                  0                          47 (24)
                                                                 0-2000 μm                  85 (43)
                                                                 ≥ 2000 μm                  67 (34)
  Diameter of the largest single tongue of invasion              \< 2 cm                    134 (67)
                                                                 ≥ 2 cm                     65 (33)
  Immunohistochemical staining[1](#T1FN1){ref-type="table-fn"}                              
  P53                                                            Complete loss              50 (39)
                                                                 Weak, patchy               41 (32)
                                                                 Diffuse, strong            37 (29)
  Cyclin D1                                                      \-                         38 (30)
                                                                 1+                         39 (31)
                                                                 2+                         49 (39)
  EGFR                                                           \-                         52 (41)
                                                                 1+                         44 (34)
                                                                 2+                         32 (25)
  VEGF                                                           \-                         54 (44)
                                                                 1+                         34 (28)
                                                                 2+                         35 (28)

Available in tissue microarray cases.

Overall survival and recurrence-free survival
---------------------------------------------

The 5-year and 10-year overall survival rates were 81.4% and 76.4%, respectively (Figure [1](#F1){ref-type="fig"}). Forty-seven (24%) patients had documented recurrences. These recurrences occurred during 3-178 mo, with a median of 33 mo. The 5-year and 10-year recurrence-free survival rates were 80.7% and 71.9%, respectively (Figure [1](#F1){ref-type="fig"}). Mediastinal lymph nodes (21 patients, 11%) were the most frequent site of recurrence, followed by cervical lymph nodes (19 patients, 10%, with 8 left, 10 right, and 1 bilateral) (Table [2](#T2){ref-type="table"}).

![Survival curves of patients with pT1N0 esophageal squamous cell carcinoma. A: Overall survival curve. The 5-year and 10-year overall survival rates were 81.4% and 76.4%, respectively. B: Recurrence-free survival curve. The 5-year and 10-year recurrence-free survival rates were 80.7% and 71.9%, respectively.](WJG-24-5154-g001){#F1}

###### 

Sites of recurrence in the 199 pT1N0 esophageal squamous cell carcinoma patients *n* (%)

  **Site of recurrence**                                       **Total patients with recurrence**   **Patients by tumor location**   **Patients by macroscopic tumor type**                      
  ------------------------------------------------------------ ------------------------------------ -------------------------------- ---------------------------------------- -------- --------- ---------
  Local-regional recurrences[1](#T2FN1){ref-type="table-fn"}   33 (17)                              15 (48)                          14 (10)                                  4 (16)   8 (38)    25 (14)
  Anastomosis                                                  3 (2)                                3 (10)                           0                                        0        2 (10)    1 (1)
  Cervical node                                                19 (10)                              10 (32)                          7 (5)                                    2 (8)    4 (19)    15 (8)
  Mediastinal node                                             21 (11)                              9 (29)                           9 (6)                                    3 (12)   8 (38)    13 (7)
  Abdominal node                                               0                                    0                                0                                        0        0         0
  Distant recurrences[1](#T2FN1){ref-type="table-fn"}          16 (8)                               5 (16)                           8 (6)                                    3 (12)   4 (19)    12 (7)
  Lung                                                         7 (4)                                2 (6)                            5 (3)                                    0        1 (5)     6 (3)
  Liver                                                        2 (1)                                1 (3)                            0                                        1 (4)    0         2 (1)
  Bone                                                         6 (3)                                0                                4 (3)                                    2 (8)    2 (10)    4 (2)
  Brain                                                        1 (0)                                1 (3)                            0                                        0        0         1 (1)
  Pleura                                                       3 (2)                                2 (6)                            1 (1)                                    0        1 (5)     2 (1)
  Distant node                                                 0                                    0                                0                                        0        0         0
  Multiple site recurrences                                    15 (8)                               7 (23)                           6 (4)                                    2 (8)    5 (24)    10 (6)
  Mediastinal node and bone                                    2 (1)                                0                                1 (1)                                    1 (4)    1 (5)     1 (1)
  Mediastinal node, cervical node, and bone                    1 (1)                                0                                0                                        1 (4)    0         1 (1)
  Mediastinal node, pleura, and bone                           1 (1)                                0                                1 (1)                                    0        0         1 (1)
  Mediastinal node and cervical node                           3 (1)                                2 (6)                            1 (1)                                    0        1 (5)     2 (1)
  Cervical node and lung                                       1 (1)                                0                                1 (1)                                    0        0         1 (1)
  Mediastinal node, cervical node, and anastomosis             1 (1)                                1 (3)                            0                                        0        1 (5)     0
  Mediastinal node, cervical node, anastomosis, and pleura     1 (1)                                1 (3)                            0                                        0        1 (5)     0
  Mediastinal node, cervical node, and lung                    2 (1)                                1 (3)                            1 (1)                                    0        1 (5)     1 (1)
  Cervical node, bone, and lung                                1 (1)                                0                                1 (1)                                    0        0         1 (1)
  Mediastinal node, liver, and lung                            1 (1)                                1 (3)                            0                                        0        0         1 (1)
  Mediastinal node and brain                                   1 (1)                                1 (3)                            0                                        0        0         1 (1)
  Unknown sites                                                10 (5)                               1 (3)                            8 (6)                                    1 (4)    1 (5)     9 (5)
  Total recurrences                                            47 (24)                              16 (52)                          25 (17)                                  6 (24)   10 (48)   37 (21)

Including the patients with multiple site recurrences.

Analysis of factors predicting tumor recurrence
-----------------------------------------------

Using the Kaplan-Meier method, preoperative clinical symptoms, tumor location, macroscopic tumor type, tumor invasion depth level, degree of differentiation, angiolymphatic invasion, tumor thickness, submucosal invasion thickness, and diameter of the largest single tongue of invasion were significantly associated with recurrence-free survival (*P* \< 0.05) (Table [3](#T3){ref-type="table"}).

###### 

Relationship of clinicopathological parameters with recurrence-free survival and tumor recurrence in the 199 pT1N0 esophageal squamous cell carcinoma patients *n* (%)

  **Parameter**                                                                             **Total**   **Recurrences**   **Kaplan-Meier analysis**   **Univariate Cox proportional hazards analysis**                                                  
  -------------------------------------------------------------- -------------------------- ----------- ----------------- --------------------------- -------------------------------------------------- ---------- ----------- ------------ ---------- ----------
  Clinical variable                                                                                                                                                                                                                                     
  Sex                                                            Male                       142         33 (23)           81                          71.6                                               0.97       1                                   
                                                                 Female                     57          14 (25)           80                          72.7                                                          1.011       0.54-1.89    0.97       
  Age (yr)                                                       \< 60                      121         28 (23)           79.2                        74.1                                               0.6        1                                   
                                                                 ≥ 60                       78          19 (24)           82.9                        66.4                                                          1.17        0.65-2.10    0.6        
  Symptoms                                                       No                         13          0                 100                         100                                                0.03       1                                   
                                                                 Yes                        186         47 (25)           79.2                        69.8                                                          23.54       0.28-2017    0.16       
  Endoscopic variable                                                                                                                                                                                                                                   
  Tumor location                                                 Upper thoracic             31          15 (48)           55.9                        44.7                                               \< 0.001   3.46        1.83-6.54    \< 0.001   
                                                                 Middle thoracic            143         26 (18)           85.2                        78.5                                                          1                                   
                                                                 Lower thoracic             25          6 (24)            86.5                        65.4                                                          1.49        0.61-3.63    0.38       
  Tumor size (endoscopically)                                    \< 2 cm                    59          16 (27)           79.3                        69.7                                               0.53       1                                   
  ≥ 2 cm                                                         140                        31 (22)     81.2              73                                                                             0.82       0.45-1.51   0.53                    
  Macroscopic                                                    Erosive                    73          12 (16)           87.2                        78                                                 0.001      1                                   
  tumor type                                                     Papillary                  26          4 (15)            90.2                        90.2                                                          0.98        0.32-3.06    0.98       
                                                                 Plaque-like                79          21 (27)           75.8                        68.6                                                          1.64        0.81-3.25    0.13       
                                                                 Ulcerative                 9           6 (67)            53.3                        26.7                                                          6.06        2.26-16.26   \< 0.001   
                                                                 Intraluminal mass          12          4 (33)            74.1                        49.4                                                          3.94        1.26-12.32   0.02       
  Standard histopathological variable                                                                                                                                                                                                                   
  Tumor invasion depth level                                     m2                         21          1 (5)             94.1                        94.1                                               0.04       1.52        1.14-1.97               0.004
  m3                                                             26                         3 (12)      96.2              88.1                                                                                                                          
  sm1                                                            18                         4 (22)      81.4              81.4                                                                                                                          
  sm2                                                            45                         11 (25)     83.8              74.8                                                                                                                          
  sm3                                                            89                         28 (31)     70.6              58.6                                                                                                                          
  Degree of differentiation                                      Well                       39          10 (26)           79.5                        65                                                 0.02       1                                   
  Moderate                                                       76                         15 (20)     84.7              82                                                                             0.73       0.33-1.63   0.44                    
                                                                 Poor                       56          13 (23)           80.7                        67.8                                                          0.92        0.40-2.11    0.92       
                                                                 Basaloid                   19          8 (42)            58.3                        35                                                            2.88        1.13-7.38    0.03       
                                                                 Spindle cell/sarcomatoid   9           1 (11)            88.9                        88.9                                                          0.54        0.07-4.21    0.55       
  Angiolymphatic invasion                                        No                         172         33 (19)           84.6                        75.3                                               \< 0.001   1                                   
  Yes                                                            27                         14 (52)     55.4              49.9                                                                           3.48       1.85-6.52   \< 0.001                
  Multicentric invasive lesions                                  No                         183         45 (25)           80.2                        70.9                                               0.42       1                                   
  Yes                                                            16                         2 (13)      86.5              86.5                                                                           0.56       0.14-2.32   0.42                    
  Number of lymph nodes dissected                                \< 14                      90          24 (27)           72.7                        70.2                                               0.25       1                                   
  ≥ 14                                                           109                        23 (21)     87.2              73.8                                                                           0.72       0.41-1.27   0.26                    
  Measured histopathological variable                                                                                                                                                                                                                   
  Tumor thickness                                                \< 3000 μm                 85          13 (15)           90                          79.3                                               0.005      1                                   
                                                                 ≥ 3000 μm                  114         34 (30)           73.2                        65.7                                                          2.41        1.27-4.56    0.007      
  Submucosal                                                     0                          47          4 (9)             95.5                        90.5                                               0.001      2.24        1.44-3.46               \< 0.001
  invasion thickness                                             1-2000 μm                  85          19 (22)           82.8                        74.4                                                                                              
  ≥ 2000 μm                                                      67                         24 (36)     67.4              56.4                                                                                                                          
  Diameter of the                                                \< 2 cm                    134         27 (20)           85.5                        75.7                                               0.008      1                                   
  largest single tongue of invasion                              ≥ 2 cm                     65          20 (31)           70.1                        64.1                                                          2.15        1.20-3.85    0.01       
  Immunohistochemical staining[1](#T3FN1){ref-type="table-fn"}                                                                                                                                                                                          
  P53                                                            Complete loss              50          19 (38)           64.8                        59.5                                               0.33       2.43        1.02-5.79    0.045      
                                                                 Weak, patchy               41          7 (17)            81.8                        81.8                                                          1                                   
                                                                 Diffuse, strong            37          12 (33)           88.6                        78.2                                                          1.88        0.74-4.77    0.19       
  Cyclin D1                                                      \-                         38          14 (37)           71.3                        56.4                                               0.88       0.93        0.64-1.36               0.72
                                                                 1+                         39          11 (28)           80.7                        73.7                                                                                              
                                                                 2+                         49          14 (29)           68.7                        68.7                                                                                              
  EGFR                                                           \-                         52          13 (25)           82.9                        75.6                                               0.27       1.15        0.78-1.69               0.49
                                                                 1+                         44          17 (39)           65.6                        51.3                                                                                              
                                                                 2+                         32          9 (28)            70.2                        68                                                                                                
  VEGF                                                           \-                         54          15 (28)           76                          67.3                                               0.59       1.05        0.72-1.54               0.79
                                                                 1+                         34          12 (35)           74.1                        59.6                                                                                              
                                                                 2+                         35          10 (29)           72.2                        72.2                                                                                              

Available in tissue microarray cases. HR: Hazard ratio; CI: Confidence interval; 5-yr RFS: 5-year recurrence free survival; 10-yr RFS: 10-year recurrence free survival; NA: Not associated.

In univariate Cox regression, upper thoracic tumor location, ulcerative or intraluminal mass macroscopic tumor type, invasion depth level, basaloid histology, angiolymphatic invasion, tumor thickness, submucosal invasion thickness, diameter of the largest single tongue of invasion, and complete loss of p53 expression were significantly associated with tumor recurrence (*P* \< 0.05) (Table [3](#T3){ref-type="table"}). In multivariate Cox regression, upper thoracic tumor location, angiolymphatic invasion, and submucosal invasion thickness were independent significant predictors of recurrence (Table [4](#T4){ref-type="table"}).

###### 

Multivariate Cox proportional hazard models for tumor recurrence in the 199 pT1N0 esophageal squamous cell carcinoma patients

  **Parameter**                                     **HR**      **95%CI**   **Global *P***   ***P*-for-trend**
  ------------------------------- ----------------- ----------- ----------- ---------------- -------------------
  Tumor location                  Upper thoracic    3.26        1.70-6.27   \< 0.001         
                                  Middle thoracic   1                                        
                                  Lower thoracic    1.05        0.43-2.59   0.91             
  Angiolymphatic invasion         3.42              1.80-6.52   \< 0.001                     
  Submucosal invasion thickness   2.06              1.30-3.27               0.002            

HR: Hazard ratio; CI: Confidence interval.

A nomogram for predicting tumor recurrence with these three independent significant predictors is shown in Figure [2](#F2){ref-type="fig"}. The nomogram had a concordance index of 0.752.

![Nomogram for predicting the probability of recurrence-free survival of pT1N0 esophageal squamous cell carcinoma. The nomogram has eight rows. The first row is the point assignment for each variable. For each individual patient, each variable is assigned a point value in accordance with the clinicopathological characteristics (rows 2-4, angiolymphatic invasion, submucosal invasion thickness, and tumor location) by delineating a vertical line between the exact variable value and the point assignment line. Thereafter, the Total Points (row 5) can be obtained by summing all of the assigned points for the three variables. Finally, the probability of 2-, 5-, and 10-year RFS (recurrence-free survival) can be predicted by drawing a vertical line between the Total Points and the probability rows (rows 6-8, respectively).](WJG-24-5154-g002){#F2}

Analysis of factors predicting distant tumor recurrence
-------------------------------------------------------

Sixteen cases had well-documented distant recurrences. The lung (7 patients, 4%) was the most frequent site of distant recurrence, followed by the bone (6 patients, 3%) (Table [2](#T2){ref-type="table"}). The time to distant recurrence ranged from 3-192 mo, with a median of 39 mo.

In univariate Cox regression, upper thoracic tumor location, ulcerative or intraluminal mass macroscopic tumor type, basaloid histology, and angiolymphatic invasion were significantly associated with distant recurrence (*P* \< 0.05). In multivariate Cox regression, upper thoracic tumor location and angiolymphatic invasion were independent predictors of distant recurrence (Table [5](#T5){ref-type="table"}).

###### 

Relationship between clinicopathological parameters and distant tumor recurrence in the 189 informative patients^1^

  **Univariate Cox proportional hazards analysis**                                                                                                                                
  -------------------------------------------------------------- -------------------------- ----------- ----------------------------- ------------ ------------- ---------------- -------------------
  **Parameter**                                                                             **Total**   **Distant recurrences (%)**   **HR**       **95%CI**     **Global *P***   ***P*-for-trend**
                                                                                                                                                                                  
  Clinical variables                                                                                                                                                              
  Sex                                                            Male                       136         14 (10)                       1                                           
                                                                 Female                     53          2 (4)                         0.33         0.07-1.44     0.14             
  Age (yr)                                                       \< 60                      118         8 (7)                         1                                           
                                                                 ≥ 60                       71          8 (11)                        2.18         0.79-6.02     0.13             
  Symptoms                                                       No                         13          0                             1                                           
                                                                 Yes                        176         16 (9)                        23.59        0.01-40030    0.41             
  Endoscopic variables                                                                                                                                                            
  Tumor location                                                 Upper thoracic             30          5 (17)                        3.56         1.15-11.07    0.03             
                                                                 Middle thoracic            135         8 (6)                         1                                           
                                                                 Lower thoracic             24          3 (13)                        2.37         0.63-8.94     0.2              
  Tumor size (measured endoscopically)                           \< 2 cm                    55          6 (11)                        1                                           
  ≥ 2 cm                                                         134                        10 (8)      0.76                          0.27-2.09    0.59                           
  Macroscopic type                                               Erosive                    71          5 (7)                         1                                           
                                                                 Papillary                  26          2 (8)                         1.11         0.21-5.75     0.9              
                                                                 Plaque-like                72          5 (7)                         0.95         0.27-3.31     0.94             
                                                                 Ulcerative                 8           2 (25)                        5.58         1.06-29.32    0.04             
                                                                 Intraluminal mass          12          2 (17)                        5.41         1.02-28.68    0.047            
  Standard histopathological variable                                                                                                                                             
  Tumor invasion depth level                                     m2                         21          0                             1.42         0.91-2.21                      0.13
  m3                                                             26                         2 (8)                                                                                 
                                                                 sm1                        16          1 (6)                                                                     
                                                                 sm2                        43          4 (9)                                                                     
                                                                 sm3                        83          9 (11)                                                                    
  Degree of differentiation                                      Well                       36          1 (3)                         1                                           
  Moderate                                                       73                         5 (7)       2.19                          0.25-18.98   0.48                           
                                                                 Poor                       54          6 (11)                        3.93         0.47-32.89    0.21             
                                                                 Basaloid                   17          3 (18)                        12.4         1.27-121.08   0.03             
                                                                 Spindle cell/sarcomatoid   9           1 (11)                        5.73         0.35 -92.90   0.22             
  Angiolymphatic invasion                                        No                         166         11 (7)                        1                                           
  Yes                                                            23                         5 (22)      3.38                          1.15-9.93    0.03                           
  Multicentric invasive lesions                                  No                         173         15 (9)                        1                                           
  Yes                                                            16                         1 (6)       0.92                          0.12-7.00    0.93                           
  Number of lymph nodes dissected                                \< 14                      85          7 (8)                         1                                           
  ≥ 14                                                           104                        9 (9)       0.95                          0.36-2.57    0.93                           
  Measured histopathological variable                                                                                                                                             
  Tumor thickness                                                \< 3000 μm                 82          6 (7)                         1                                           
                                                                 ≥ 3000 μm                  107         10 (9)                        1.53         0.56-4.21     0.42             
  Submucosal                                                     0                          47          2 (4)                         1.88         0.91-3.90                      0.09
  invasion thickness                                             \< 2000 μm                 80          7 (9)                                                                     
                                                                 ≥ 2000 μm                  62          7 (11)                                                                    
  Diameter of the                                                \< 2 cm                    126         9 (7)                         1                                           
  largest invasive lesion                                        ≥ 2 cm                     63          7 (11)                        2.56         0.92-7.15     0.07             
  Immunohistochemical staining[2](#T5FN1){ref-type="table-fn"}                                                                                                                    
  P53                                                            Complete loss              47          6 (13)                        1.78         0.44-7.16     0.42             
                                                                 Weak, patchy               40          3 (8)                         1                                           
                                                                 Diffuse, strong            34          6 (18)                        2.31         0.58-9.25     0.24             
  Cyclin D1                                                      \-                         35          5 (14)                        0.94         0.51-1.74                      0.84
                                                                 \+                         37          5 (14)                                                                    
                                                                 ++                         47          5 (11)                                                                    
  EGFR                                                           \-                         52          9 (17)                        0.63         0.31-1.28                      0.2
                                                                 \+                         40          4 (10)                                                                    
                                                                 ++                         29          2 (7)                                                                     
  VEGF                                                           \-                         50          6 (12)                        0.95         0.50-1.81                      0.88
                                                                 \+                         33          3 (9)                                                                     
                                                                 ++                         33          4 (12)                                                                    
  Multivariate Cox proportional hazards analysis                                                                                                                                  
  Parameter                                                                                                                                                                       
  Tumor location                                                 Upper thoracic                                                       3.83         1.23-11.96    0.02             
                                                                 Middle thoracic                                                      1                                           
                                                                 Lower thoracic                                                       1.95         0.50-7.54     0.34             
  Angiolymphatic invasion                                                                                                             3.55         1.17-10.77    0.03             

^1^Excluding 10 patients with an unknown site of recurrence;

Available in tissue microarray cases. HR: Hazard ratio; CI: Confidence interval; 5-yr RFS: 5-year recurrence free survival; 10-yr RFS: 10-year recurrence free survival; NA: Not associated.

Analysis of factors predicting early tumor recurrence
-----------------------------------------------------

Among the 47 cases with recurrences, 18 (38%) had early recurrences (≤ 24 mo after surgery).

In univariate logistic regression, upper thoracic tumor location, ulcerative or intraluminal mass macroscopic tumor type, angiolymphatic invasion, tumor invasion depth level, tumor thickness, submucosal invasion thickness, and diameter of the largest single tongue of invasion were significantly associated with early recurrence (*P* \< 0.05). Multivariate logistic regression showed that upper thoracic tumor location, angiolymphatic invasion, submucosal invasion thickness, and diameter of the largest single tongue of invasion were independent predictors of early recurrence (Table [6](#T6){ref-type="table"}).

###### 

Relationship between clinicopathological parameters and the likelihood of having early recurrence (≤ 24 mo) in the 199 pT1N0 esophageal squamous cell carcinoma patients *n* (%)

  **Univariate logistic regression**                                                                                                                                          
  -------------------------------------------------------------- -------------------------- ----------- ---------------------- ---------------- ------------ ---------------- -------------------
  **Parameter**                                                                             **Total**   **Early recurrence**   **Odds ratio**   **95%CI**    **Global *P***   ***P*-for-trend**
                                                                                                                                                                              
  Clinical variable                                                                                                                                                           
  Sex                                                            Male                       142         12 (9)                 1                                              
                                                                 Female                     57          6 (11)                 1.28             0.45-3.58    0.65             
  Age (yr)                                                       \< 60                      121         15 (12)                1                                              
                                                                 ≥ 60                       78          3 (4)                  0.28             0.08-1.01    0.052            
  Endoscopic variable                                                                                                                                                         
  Tumor location                                                 Upper thoracic             31          9 (29)                 7.95             2.68-23.54   \< 0.001         
                                                                 Middle thoracic            143         7 (5)                  1                                              
                                                                 Lower thoracic             25          2 (8)                  1.69             0.33-8.64    0.53             
  Tumor size (endoscopically)                                    \< 2 cm                    59          4 (7)                  1                                              
  ≥ 2 cm                                                         140                        14 (10)     1.53                   0.48-4.85        0.47                          
  Macroscopic                                                    Erosive                    73          4 (6)                  1                                              
  tumor types                                                    Papillary                  26          1 (4)                  0.69             0.07-6.47    0.75             
                                                                 Plaque-like                79          7 (9)                  1.68             0.47-5.98    0.43             
                                                                 Ulcerative                 9           3 (33)                 8.63             1.55-47.86   0.01             
                                                                 Intraluminal mass          12          3 (25)                 5.75             1.10-29.95   0.04             
  Standard histopathological variable                                                                                                                                         
  Tumor invasion depth level                                     m2                         21          0                      1.78             1.05-3.01                     0.03
  m3                                                             26                         1 (4)                                                                             
  sm1                                                            18                         2 (11)                                                                            
  sm2                                                            45                         2 (4)                                                                             
  sm3                                                            89                         13 (15)                                                                           
  Degree of differentiation                                      Well                       39          3 (8)                  1                                              
  Moderate                                                       76                         6 (8)       1.03                   0.24-4.35        0.97                          
                                                                 Poor                       56          4 (7)                  0.92             0.20-4.38    0.92             
                                                                 Basaloid                   19          4 (21)                 3.2              0.64-16.07   0.16             
                                                                 Spindle cell/sarcomatoid   9           1 (11)                 1.5              0.14-16.36   0.74             
  Angiolymphatic invasion                                        No                         172         10 (6)                 1                                              
  Yes                                                            27                         8 (30)      6.82                   2.40-19.38       \< 0.001                      
  Multicentric invasive lesions                                  No                         183         17 (9)                 1                                              
  Yes                                                            16                         2 (13)      0.65                   0.08-5.24        0.69                          
  Number of lymph nodes dissected                                \< 14                      90          11 (12)                1                                              
  ≥ 14                                                           109                                    0.49                   0.18-1.33        0.16                          
  Measured histopathological variable                                                                                                                                         
  Tumor thickness                                                \< 3000 μm                 85          2(2)                   1                                              
  ≥ 3000 μm                                                      114                        16(14)      6.78                   1.51-30.33       0.01                          
  Submucosal invasion thickness                                  0                          47          1(2)                   4.02             1.66 -9.73                    0.001
  0-2000 μm                                                      85                         4(5)                                                                              
  ≥ 2000 μm                                                      67                         13(19)                                                                            
  Diameter of the largest single tongue of invasion              \< 2 cm                    134         5(4)                   1                                              
  ≥ 2 cm                                                         65                         13(20)      6.45                   2.19-19.00       0.001                         
  Immunohistochemical staining[1](#T6FN1){ref-type="table-fn"}                                                                                                                
  P53                                                            Complete loss              50          7 (14)                 1.34             0.36-4.98                     0.66
                                                                 Weak, patchy               41          5 (12)                 1                                              
                                                                 Diffuse, strong            37          4 (11)                 1.15             0.28-4.63                     0.85
  Cyclin D1                                                      \-                         38          4 (11)                 1.32             0.69-2.54                     0.4
                                                                 1+                         39          4 (10)                                                                
                                                                 2+                         49          8 (16)                                                                
  EGFR                                                           \-                         52          4 (8)                  1.32             0.69-2.54                     0.4
                                                                 1+                         44          8 (18)                                                                
                                                                 2+                         32          4 (13)                                                                
  VEGF                                                           \-                         54          4 (7)                  1.59             0.83-3.04                     0.16
                                                                 1+                         34          5 (15)                                                                
                                                                 2+                         35          6 (17)                                                                
  Multivariate logistic regression                                                                                                                                            
  Tumor location                                                 Upper thoracic                                                7.73             2.15-27.78   0.002            
                                                                 Middle thoracic                                               1                                              
                                                                 Lower thoracic                                                1.18             0.20-6.86    0.85             
  Angiolymphatic invasion                                                                                                      5.75             1.63-20.24   0.006            
  Submucosal invasion thickness                                                                                                2.64             0.92-7.60    0.07             
  Diameter of the largest single tongue of invasion                                                                            4.13             1.17-14.56   0.03             

Available in tissue microarray cases. OR: Odds ratio; CI: Confidence interval; NA: Not associated.

DISCUSSION
==========

We previously analyzed pT1 ESCC esophagectomy cases to identify predictors of synchronous regional lymph node metastatsis\[[@B5]\]. In the present study, we followed the pT1N0 thoracic ESCC cases further, for a median of 6 years, and investigated the risk of tumor recurrence and parameters predicting tumor recurrence. We studied the cases before 2004 when the endoscopic resection had not been performed yet in our hospital.

Consistent with our previous observation that all asymptomatic cases had no lymph node metastases, these cases also had no recurrence in our follow-up period. ESCC has a very good prognosis if detected when it is asymptomatic. This can be achieved by appropriate screening programs. However, few studies have analyzed the impact of symptoms on the prognosis of ESCC. Wang et al\[[@B14]\] observed the natural progression of untreated superficial ESCCs identified by screening in a high-risk area. Most of the patients were asymptomatic. It took a long time to progress from an early to an advanced stage, and most survived for over 5 years. Wang et al\[[@B15]\] also reported a 30-year experience with esophagectomy for superficial ESCCs identified in large-scale mass screenings in high-risk areas. Most patients were asymptomatic, and had a low recurrence rate. Natsugoe et al\[[@B16]\] also reported that asymptomatic esophageal carcinoma patients had a lower stage and a better prognosis.

Proximal tumors are known to have a more advanced stage, a lower resection rate, fewer R0 resections, more cervical and tracheobronchial lymph node metastases, and a poorer prognosis\[[@B17],[@B18]\]. The 7^th^ and 8^th^ editions of the American Joint Committee on Cancer (AJCC) staging system include tumor location as a staging factor for T2-3N0M0 ESCC cases and T3N0M0 ESCC cases, respectively\[[@B19],[@B20]\]. Few studies have focused on T1 proximal tumors. We found that the patients with upper thoracic tumors had much higher frequencies of cervical and mediastinal lymph node recurrences than other patients (Table [2](#T2){ref-type="table"}), and these proximal tumors were significantly associated with an increased risk for any recurrence (Table [3](#T3){ref-type="table"}), distant recurrence (Table [5](#T5){ref-type="table"}), and early recurrence (Table [6](#T6){ref-type="table"}). One reason for a higher frequency of cervical and mediastinal lymph node recurrences in upper thoracic cases is the characteristics of the lymphatic channels draining this area\[[@B1],[@B2]\]. We also found that tumor thickness was greater in upper thoracic tumors (data not shown), which may be another reason. Upper thoracic tumor location was also one of the independent risk factors for any recurrence, distant recurrence, and early recurrence.

We need to say that the fact that most (33/37 = 89%) of the patients in whom the locations of the recurrences were recorded had recurrences in the cervical and/or mediastinal lymph nodes raises the question of whether (macroscopic or microscopic) tumor was present at the time of surgery and could have been removed if a three-field lymph node dissection (including the cervical lymph nodes) or a more extensive two-field lymph node dissection (including more mediastinal lymph nodes) had been done. In Japan, standard treatment for clinically submucosal ESCC is esophagectomy with three-field lymphadenectomy\[[@B21]\]. It is not yet known whether all patients would benefit from cervical lymphadenectomy, which often results in more severe complications. The optimal extent of lymph node dissection in esophagectomies is an ongoing discussion among surgeons, and our data can contribute to this discussion.

There is a macroscopic tumor type which looks like a large mushroom or a big polyp, and is commonly pedunculated. It belongs to the Paris classification 0-Ip\[[@B10],[@B11]\], but it is different from other common 0-Ip cases. It can be called the intraluminal mass (fungating) type\[[@B9]\]. Most tumors of this type are spindle cell/sarcomatoid, basaloid, or poorly differentiated squamous cell carcinoma. Our previous study found that patients with ulcerative or intraluminal tumors had a high risk of lymph node metastasis\[[@B9]\]. We have now shown that they also have a significantly higher rate of recurrence.

In the current analysis, angiolymphatic invasion was significantly associated with tumor recurrence, distant recurrence, and early recurrence. We relied on HE staining to evaluate angiolymphatic invasion, and immunohistochemistry for endothelial cells was not routinely performed, in keeping with standard practice. Huang et al\[[@B8]\] reported that angiolymphatic invasion could act as a prognostic and staging factor in T1-3N0M0 ESCC.

In our previous study, patients with basaloid histology had a moderate risk of synchronous lymph node metastasis\[[@B9]\]. However, in the current study they had a high risk of recurrence, especially distant recurrence. Zhang et al\[[@B22]\] retrospectively analyzed 142 cases of basaloid ESCC, and found that the first site of recurrence was distant in 39 (54.9%) cases, distant plus loco-regional in 24 (33.8%) cases, and loco-regional alone in 8 (11.3%) cases. They concluded that basaloid ESCC frequently progresses *via* hematogenous metastasis rather than lymph node metastasis\[[@B22]\]. Saito et al\[[@B23]\] also reported that differentiated components of ESCC were most often found in sites of lymph node metastases, whereas basaloid components predominated in sites of hematogenous metastases. Thus, control of the hematogenous spread of basaloid components may lead to improved outcomes in these patients. Indeed, there is a case report of surgical intervention helping a basaloid ESCC patient with a solitary lung metastasis achieve a long-term survival\[[@B24]\].

It should be noticed that one m2 case had a cervical lymph node recurrence at nearly 5 years after esophagectomy. This case had a tumor thickness of 325 μm and no adverse parameters. Therefore, long-term follow-up is needed for all patients with T1 ESCC after endoscopic resection or esophagectomy, even when the patients have no known adverse parameters.

We have identified certain clinicopathological features that are associated with an increased risk of tumor recurrence in pT1N0 thoracic ESCC patients after esophagectomy and thoracoabdominal two-field lymphadenectomy: (1) Patients with an upper thoracic location, ulcerative or intraluminal mass tumor type, deeper tumor invasion level, basaloid histology, angiolymphatic invasion, greater tumor thickness, greater submucosal invasion thickness, greater diameter of the largest single tongue of invasion, and/or completely negative aberrant p53 expression are at greater risk of tumor recurrence. A nomogram including tumor location, angiolymphatic invasion, and submucosal invasion thickness can be used to predict the likelihood of recurrence-free survival at different times after surgery; (2) Patients with an upper thoracic tumor location and/or angiolymphatic invasion have a higher risk of distant recurrence; and (3) Patients with an upper thoracic tumor location, angiolymphatic invasion, submucosal invasion thickness, and diameter of the largest single tongue of invasion have a higher risk of early recurrence.

All patients with T1 ESCC need long-term follow-up after endoscopic resection or esophagectomy, even patients without any adverse parameters. But this analysis should help clinicians select a subset of these patients who need especially close postoperative surveillance and/or chemoradiotherapy. Additional long-term follow-up studies are needed to confirm these findings.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The prognosis of superficial (T1) esophageal squamous cell carcinoma (ESCC) is poor, compared with T1 gastric or colorectal cancer. The unfavorable prognosis of patients with T1 ESCC is due to high rates of both synchronous and metachronous metastases. Recurrences of T1 ESCC after esophagectomy are usually metachronous metastases. When recurrence occurs, the prognosis is similar in patients who were node-negative or node-positive at the time of the original surgery. However, only a few studies have evaluated the clinicopathological characteristics associated with an increased risk of a postoperative recurrence in pT1N0 ESCC patients. No previous studies have separately evaluated the clinicopathological characteristics that are associated with distant recurrence or early recurrence in pT1N0 ESCC patients.

Research motivation
-------------------

The identification of pT1N0 ESCC cases at high risk for recurrence is a very important and challenging aspect of the clinical management of these patients, to ensure appropriate use and maximum benefit of additional therapies.

Research objectives
-------------------

To investigate the clinicopathological characteristics that are associated with recurrence, distant recurrence, and early recurrence, in order to provide clues to optimal individual therapy.

Research methods
----------------

Clinicopathological characteristics associated with any recurrence or distant recurrence were evaluated using univariate and multivariate Cox proportional hazards models. Early recurrence (≤ 24 mo) and correlated parameters were assessed using univariate and multivariate logistic regression models.

Research results
----------------

We have identified certain clinicopathological features that are associated with an increased risk of tumor recurrence in pT1N0 thoracic ESCC patients. A nomogram including tumor location, angiolymphatic invasion, and submucosal invasion thickness can be used to predict the likelihood of recurrence-free survival at different times after surgery. Patients with an upper thoracic tumor location and/or angiolymphatic invasion have a higher risk of distant recurrence. Patients with an upper thoracic tumor location, angiolymphatic invasion, submucosal invasion thickness, and an greater diameter of the largest single tongue of invasion have a higher risk of early recurrence. Additional long-term follow-up studies are needed to confirm these findings.

Research conclusions
--------------------

We evaluated the clinicopathological characteristics associated with an increased risk of a postoperative recurrence and separately evaluated the clinicopathological characteristics that are associated with distant recurrence or early recurrence in pT1N0 ESCC patients. This study should help clinicians select a subset of these patients who need especially close postoperative surveillance and/or chemoradiotherapy.

Research perspectives
---------------------

Risk of tumor recurrence in pT1N0 ESCC patients can be predicted using certain clinicopathological features. This should be confirmed in more prospective studies and multi-center studies.
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